
CNIPA declares patent for crystalline form of insomnia treatment invalid
On February 25 2025, the CNIPA issued an invalidation decision, No. 584735, declaring the patent for the crystalline form of the drug lemborexant invalid. Lemborexant, also known by its trade name Dayvigo, was developed by Eisai Co. Ltd. (Eisai) and is …